QR Kod

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Background/Aims Combination immunotherapy, exemplified by atezolizumab plus bevacizumab, has become the standard of care for inoperable hepatocellular carcinoma (HCC). However, the lack of predictive biomarkers and limited understanding of response mechanisms remain a challenge. Methods Using data f...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Korean Association for the Study of the Liver 2024-10-01
Seri Bilgileri:Clinical and Molecular Hepatology
Konular:
hepatocellular carcinoma
immunotherapy
atezolizumab
bevacizumab
transcriptome
Online Erişim:http://e-cmh.org/upload/pdf/cmh-2024-0333.pdf
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller